Diabetes – Talk Bio

Schott Pharma Invests Over €100M in New Sterile Cartridge Facility at Hungary Site

3 days ago talkbio0Tagged Automation, Diabetes, expansion, Glucagon-Like Peptide 1, Hungary, Impacts, Environmental, Investments, Lukácsháza, Manufacturing, Pharma, pharma packaging, RTU cartridges, Schott, sterile cartridge facility

Schott Pharma; Hungary; sterile cartridge facility; €100 million investment; RTU cartridges; pharma packaging; manufacturing expansion; Lukácsháza; GLP-1 drugs; diabetes; automation; environmental impact

Chronic care startup Omada Health files to go public

4 weeks ago talkbio0Tagged Administration occupational activities, cardiometabolic, Chronic Care Management, Diabetes, digital health, Health, Hinge Health, Hypertensive disease, IPO, musculoskeletal conditions, revenue growth, virtual care

Chronic care management, virtual care, IPO, digital health, diabetes management, cardiometabolic health, hypertension, musculoskeletal conditions, revenue growth, Hinge Health

Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil

2 months ago talkbio0Tagged Brazil, Claros facility, Diabetes, Glucagon-Like Peptide 1, Investments, Montes, Nordisk, Obesity, Ozempic, pharmaceutical manufacturing, production, Wegovy

Novo Nordisk , GLP-1 production , Brazil investment , Wegovy and Ozempic , Diabetes treatment , Obesity treatment , Montes Claros facility , Pharmaceutical manufacturing

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

4 months ago talkbio0Tagged alpha 1-antitrypsin, Axplora, biology (field), CDMO, Chromatography, Diabetes, expansion, France, Glucagon-Like Peptide 1, Manufacturing, Mourenx, Obesity, production

Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies

FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

4 months ago talkbio0Tagged Agonist, Approved, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes, GLP-1 receptor, Kidney Diseases, Ozempic, Risk, semaglutide, United States Food and Drug Administration

Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist